BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21781137)

  • 21. Chronic antigen ingestion protects ovalbumin sensitized mice from severe manifestation of Leishmania major infection.
    Saldanha JC; Gargiulo DL; Dourado LP; Santiago HC; Menezes GB; Reis ML; Tafuri WL; Teixeira MM; Vieira LQ; Cara DC
    Parasite Immunol; 2008; 30(11-12):646-9. PubMed ID: 19067847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Leishmanization Using
    Keshavarzian N; Noroozbeygi M; Haji Molla Hoseini M; Yeganeh F
    Front Immunol; 2020; 11():1725. PubMed ID: 33193290
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J; Kaur T; Kaur S
    Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice.
    Doroud D; Zahedifard F; Vatanara A; Najafabadi AR; Rafati S
    Parasite Immunol; 2011 Jun; 33(6):335-48. PubMed ID: 21410716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
    Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
    Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis.
    Agallou M; Smirlis D; Soteriadou KP; Karagouni E
    Vaccine; 2012 Jul; 30(34):5086-93. PubMed ID: 22704924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae.
    Nateghi Rostami M; Keshavarz H; Khamesipour A
    Trop Biomed; 2010 Apr; 27(1):89-102. PubMed ID: 20562818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes.
    Lasri S; Sahibi H; Sadak A; Jaffe CL; Rhalem A
    Vet Res; 1999; 30(5):441-9. PubMed ID: 10543378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of anti-leishmanial activity by induction of nitric oxide and inhibition of prostaglandin in Balb/c mice infected with Leishmania major.
    Nahrevanian H; Hajihosseini R; Arjmand M; Farahmand M; Ghasemi F
    Southeast Asian J Trop Med Public Health; 2009 Nov; 40(6):1188-98. PubMed ID: 20578452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
    Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
    J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous immunization against Leishmania major - infection in mice: efficacy of formalin-killed promastigotes combined with adjuvants.
    Mutiso JM; Macharia JC; Mutisya RM; Taracha E
    Rev Inst Med Trop Sao Paulo; 2010; 52(2):95-100. PubMed ID: 20464130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.
    Sharifi I; FeKri AR; Aflatonian MR; Khamesipour A; Nadim A; Mousavi MR; Momeni AZ; Dowlati Y; Godal T; Zicker F; Smith PG; Modabber F
    Lancet; 1998 May; 351(9115):1540-3. PubMed ID: 10326536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
    Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
    J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S; Ghaemimanesh F; Zahedifard F
    Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.
    Jaafari MR; Ghafarian A; Farrokh-Gisour A; Samiei A; Kheiri MT; Mahboudi F; Barkhordari F; Khamesipour A; McMaster WR
    Vaccine; 2006 Jul; 24(29-30):5708-17. PubMed ID: 16740346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
    Nahrevanian H; Farahmand M; Aghighi Z; Assmar M; Amirkhani A
    Exp Parasitol; 2007 Jul; 116(3):233-40. PubMed ID: 17335813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.